Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Piper Sandler remains bullish on Aimmune after updated data for Palforzia » 11:02
06/08/20
06/08
11:02
06/08/20
11:02
AIMT

Aimmune

$18.50 /

+0.52 (+2.89%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond remains Overweight rated on Aimmune shares following updated data for Palforzia disclosed at EAACI. In addition to positive treatment satisfaction data, the company presented two-year data from the Phase 3 PALISADE follow-on study, ARC004, he notes. With continued immunomodulation now out to two years in combination with ongoing desensitization to peanut antigens, the analyst sees the update as incrementally positive for the program. Given his expectations that the Palforzia launch, which has been paused due to the pandemic, will pick up in the second half of the year, with pent-up demand still significant, he likes the setup for shares moving forward and remains a buyer. He has a $60 price target on the stock.

ShowHide Related Items >><<
AIMT Aimmune
$18.50 /

+0.52 (+2.89%)

AIMT Aimmune
$18.50 /

+0.52 (+2.89%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
AIMT Aimmune
$18.50 /

+0.52 (+2.89%)

AIMT Aimmune
$18.50 /

+0.52 (+2.89%)

AIMT Aimmune
$18.50 /

+0.52 (+2.89%)

Hot Stocks
Aimmune announces two-year Palforzia data in patients with peanut allergy » 08:15
06/08/20
06/08
08:15
06/08/20
08:15
AIMT

Aimmune

$17.98 /

+0.13 (+0.73%)

Aimmune announced new…

Aimmune announced new two-year data that suggest long-term efficacy of daily treatment with Palforzia in patients with peanut allergy. Patients dosed daily in the study also showed ongoing immunomodulation and higher rates of desensitization that increased over time compared to those patients who were administered non-daily dosing. Furthermore, the majority of patients in the daily dosing groups reported lower adverse event, or AE, rates compared to those in the non-daily dosing groups, with an overall safety profile of long-term daily dosing with Palforzia that was better than non-daily dosing. These two-year results from ARC004, a follow-on study to the pivotal phase 3 PALISADE trial, were presented during the digital European Academy of Allergy and Clinical Immunology, or EAACI, Congress and are available for on-demand viewing at EAACI scientific programme website. A greater proportion of patients who continued daily long-term dosing with Palforzia in ARC004 completed the study compared to those patients in the non-daily treatment groups. Furthermore, after two years of daily treatment with Palforzia, more than 80% of patients undergoing the food challenge demonstrated desensitization to 2000 mg peanut protein. Desensitization rates associated with Palforzia treatment were higher in the daily dosing groups compared to the non-daily dosing groups; within the daily dosing groups, desensitization rates improved with duration of therapy. Changes in immunologic measures showed ongoing immunomodulation during the first two years of treatment with Palforzia with further modulation of immunologic and improvement in clinical parameters in subsequent years anticipated to occur. Patients in the two daily dosing groups also reported fewer treatment-related adverse events, or TRAE, when adjusted for the number of patient-years of exposure compared to the three non-daily dosing groups. Adverse events in the daily dosing groups were mostly mild to moderate with only three patients reporting severe events observed in over 100 patient-years of exposure. The overall rate of AE-related discontinuations was low but slightly higher in the longer-term non-daily dosing groups. Across treatment groups, Palforzia appeared to be well tolerated and was consistent with previous studies with no new safety concerns.

ShowHide Related Items >><<
AIMT Aimmune
$17.98 /

+0.13 (+0.73%)

AIMT Aimmune
$17.98 /

+0.13 (+0.73%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
AIMT Aimmune
$17.98 /

+0.13 (+0.73%)

AIMT Aimmune
$17.98 /

+0.13 (+0.73%)

AIMT Aimmune
$17.98 /

+0.13 (+0.73%)

Over a month ago
Hot Stocks
Aimmune announces findings from APPEAL-1 study on peanut allergy impact » 07:47
05/28/20
05/28
07:47
05/28/20
07:47
AIMT

Aimmune

$17.13 /

-0.005 (-0.03%)

Aimmune announced that…

Aimmune announced that findings from APPEAL-1, a multi-dimensional pan-European study assessing the psychosocial effect and impact of living with peanut allergy, were published in Allergy, one of the official journals of European Academy of Allergy and Clinical Immunology. The study, published in two parts, highlights the impact peanut allergy has on every aspect of allergic individuals' and their caregivers' lives, including the uncertainty they feel around how to manage frightening and debilitating reactions and concerns about the feasibility of ongoing avoidance. APPEAL-1 is the first and largest quantitative study to validate and bring attention to the burden and psychosocial impact with which allergic individuals and their caregivers are challenged in their daily lives. The findings illustrate the impact of living with the condition, and how attempting to avoid peanuts every day can be a major source of stress, fear and anxiety, clouded by the persistent worry of accidental exposure for both the allergic individual and their caregiver. The data also demonstrate that across Europe there is insufficient education for coping and living with the disease and the management of reactions. Ambiguity over how to use rescue medicine and the potential trauma of necessitating its use is an additional burden that people with peanut allergy currently face. The APPEAL-1 Part A data provide meaningful insights into the experience of those with peanut allergy related to their reactions and disease management. Of the 1,300 survey participants, 45% rate their worst allergy reactions as severe, and 31% require the use of rescue medicine and hospitalization for their worst reaction. Of this latter group, percentages are higher in younger age groups; 35% in children and 42% in teenagers, compared with 26% in adults. Despite this, more than a quarter had never been prescribed an adrenaline auto-injector, or AAI, and only 24% of all respondents received training on what to do in an emergency. Of those that had been prescribed an AAI, only a third had received training on how to use it. Overall, 87.4% report multiple symptoms during their worst allergic reactions, the most common symptoms included swelling, breathing difficulties/wheezing and itching mouth or throat tightness. Almost one third report gastrointestinal symptoms. Comorbidities are common, with 42%, 50% and 79% reporting comorbid allergic rhinitis, asthma, and other food allergy, respectively. Nearly half of all respondents describe living with the disease as "more" or "much more" expensive than living without the disease, pointing to a financial burden associated with managing peanut allergy. Most respondents note indirect costs associated with the extra time needed for planning day-to-day activities and special events. The APPEAL-1 Part B data show the impact on individuals' freedom of choice in daily activities; feelings and emotions; impacts of bullying, and their ability to cope with peanut allergy. Of the 1,846 survey respondents: 90% report feeling frustrated and stressed, with over a third having frequent feelings of anxiety. A total of 65% report feelings of isolation and 43% report experiencing bullying. Overall, 89% report feeling restricted on where to eat out and 84% feel limited on buying food. Moreover, respondents report limitations in other areas of their lives not related to food, such as choice of schools, socializing and going to special occasions. More than half worry about exposure during social occasions where food is not involved. Within these data, there are some cross-country differences observed. In Germany, the highest rates of anxiety are reported, nearly a third said they had coped "not at all well" with peanut allergy at first diagnosis and nearly all respondents report restrictions in socializing and holidays. In France, nearly all respondents state they are made to feel "different" in a negative way and 74% report feelings of isolation. More than half of respondents in the UK report being bullied about their peanut allergy. Confidence in recognizing allergic reaction symptoms and on how and when to use rescue medicine was low in Germany and France. In Germany, only 22% feel "extremely confident" in recognizing allergic reaction symptoms, and only 12% know when to use rescue medicine. In France, only 14% of respondents report knowing how to use it.

ShowHide Related Items >><<
AIMT Aimmune
$17.13 /

-0.005 (-0.03%)

AIMT Aimmune
$17.13 /

-0.005 (-0.03%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
AIMT Aimmune
$17.13 /

-0.005 (-0.03%)

AIMT Aimmune
$17.13 /

-0.005 (-0.03%)

AIMT Aimmune
$17.13 /

-0.005 (-0.03%)

Conference/Events
RBC Capital to hold a virtual conference » 04:55
05/20/20
05/20
04:55
05/20/20
04:55
ADUS

Addus HomeCare

$89.04 /

-0.89 (-0.99%)

, HOOK

Hookipa Pharma

$9.27 /

-0.88 (-8.67%)

, KPTI

Karyopharm

$17.68 /

-0.97 (-5.20%)

, UHS

Universal Health

$101.01 /

+0.55 (+0.55%)

, ENTA

Enanta

$54.33 /

-3.25 (-5.64%)

, REGN

Regeneron

$557.61 /

-1.76 (-0.31%)

, ARAV

Aravive

$12.27 /

-0.31 (-2.46%)

, IMGN

ImmunoGen

$4.62 /

-0.14 (-2.94%)

, HCA

HCA Healthcare

$103.94 /

-1.63 (-1.54%)

, PFE

Pfizer

$37.68 /

-0.4 (-1.05%)

, BCEL

Atreca

$18.06 /

-0.69 (-3.68%)

, JAZZ

Jazz Pharmaceuticals

$113.07 /

-3.23 (-2.78%)

, OVID

Ovid Therapeutics

$4.46 /

+0.29 (+6.95%)

, ACAD

Acadia

$51.02 /

-1.05 (-2.02%)

, BMRN

BioMarin

$93.88 /

-1.46 (-1.53%)

, EHTH

eHealth

$124.65 /

-2.38 (-1.87%)

, EXEL

Exelixis

$24.87 /

-0.79 (-3.08%)

, INO

Inovio

$14.56 /

+0.41 (+2.90%)

, SPRT

Support.com

$1.25 /

-0.01 (-0.79%)

, CYH

Community Health

$3.11 /

-0.05 (-1.58%)

, INCY

Incyte

$94.92 /

-1.58 (-1.64%)

, AGIO

Agios Pharmaceuticals

$47.89 /

-0.93 (-1.90%)

, EGRX

Eagle Pharmaceuticals

$53.24 /

-1.26 (-2.31%)

, IGMS

IGM Biosciences

$52.75 /

-2.66 (-4.80%)

, AIMT

Aimmune

$16.55 /

-0.92 (-5.27%)

, VRCA

Verrica Pharmaceuticals

$10.11 /

-0.62 (-5.78%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$101.01 /

+0.55 (+0.55%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$54.33 /

-3.25 (-5.64%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$557.61 /

-1.76 (-0.31%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
ARAV Aravive
$12.27 /

-0.31 (-2.46%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$37.68 /

-0.4 (-1.05%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.06 /

-0.69 (-3.68%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$51.02 /

-1.05 (-2.02%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$124.65 /

-2.38 (-1.87%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.56 /

+0.41 (+2.90%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.25 /

-0.01 (-0.79%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$94.92 /

-1.58 (-1.64%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

Conference/Events
RBC Capital to hold a virtual conference » 08:45
05/19/20
05/19
08:45
05/19/20
08:45
ADUS

Addus HomeCare

$89.93 /

+5.99 (+7.14%)

, HOOK

Hookipa Pharma

$10.15 /

+0.78 (+8.32%)

, KPTI

Karyopharm

$18.65 /

-0.4 (-2.10%)

, UHS

Universal Health

$100.46 /

+7.86 (+8.49%)

, ENTA

Enanta

$57.58 /

+2.25 (+4.07%)

, REGN

Regeneron

$559.37 /

-16.71 (-2.90%)

, ARAV

Aravive

$12.58 /

+0.11 (+0.88%)

, IMGN

ImmunoGen

$4.76 /

+0.33 (+7.45%)

, HCA

HCA Healthcare

$105.57 /

+6.83 (+6.92%)

, PFE

Pfizer

$38.08 /

+0.31 (+0.82%)

, BCEL

Atreca

$18.75 /

-0.44 (-2.29%)

, JAZZ

Jazz Pharmaceuticals

$116.30 /

+4.79 (+4.30%)

, OVID

Ovid Therapeutics

$4.17 /

+0.09 (+2.21%)

, ACAD

Acadia

$52.07 /

+1.23 (+2.42%)

, BMRN

BioMarin

$95.34 /

+1.595 (+1.70%)

, EHTH

eHealth

$127.03 /

+9.13 (+7.74%)

, EXEL

Exelixis

$25.66 /

-0.07 (-0.27%)

, INO

Inovio

$14.15 /

+0.73 (+5.44%)

, SPRT

Support.com

$1.26 /

+0.06 (+5.00%)

, CYH

Community Health

$3.16 /

+0.435 (+15.99%)

, INCY

Incyte

$96.50 /

+0.37 (+0.38%)

, AGIO

Agios Pharmaceuticals

$48.82 /

+2.38 (+5.12%)

, EGRX

Eagle Pharmaceuticals

$54.50 /

+1.74 (+3.30%)

, IGMS

IGM Biosciences

$55.41 /

-3.59 (-6.08%)

, AIMT

Aimmune

$17.47 /

+1.1 (+6.72%)

, VRCA

Verrica Pharmaceuticals

$10.73 /

+0.47 (+4.58%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$100.46 /

+7.86 (+8.49%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$57.58 /

+2.25 (+4.07%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$559.37 /

-16.71 (-2.90%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
ARAV Aravive
$12.58 /

+0.11 (+0.88%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$38.08 /

+0.31 (+0.82%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.75 /

-0.44 (-2.29%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$52.07 /

+1.23 (+2.42%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$127.03 /

+9.13 (+7.74%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.15 /

+0.73 (+5.44%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.26 /

+0.06 (+5.00%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$96.50 /

+0.37 (+0.38%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

Recommendations
Aimmune price target lowered to $19 from $29 at Credit Suisse » 07:28
05/13/20
05/13
07:28
05/13/20
07:28
AIMT

Aimmune

$17.00 /

-0.89 (-4.97%)

Credit Suisse analyst…

Credit Suisse analyst Evan Seigerman lowered the firm's price target on Aimmune to $19 from $29 and keeps a Neutral rating on the shares. The analyst notes that Palforzia launch is functionally on hold during the pandemic. While the company's interactions with allergists and caregivers indicate that underlying interest remains, the analyst believes that Palforzia's in-office monitoring requirement for up-dosing poses a substantial headwind to uptake while the pandemic persists. He is also uncertain that demand will ramp substantially once stay-at-home orders relax. Seigerman thinks the increased risk of anaphylaxis from up-dosing may be a hindrance to many parents, especially while the SARS-CoV-2 virus circulates.

ShowHide Related Items >><<
AIMT Aimmune
$17.00 /

-0.89 (-4.97%)

AIMT Aimmune
$17.00 /

-0.89 (-4.97%)

05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
04/06/20 Citi
DBV's Viaskin Peanut more likely than not to be approved, says Citi
AIMT Aimmune
$17.00 /

-0.89 (-4.97%)

AIMT Aimmune
$17.00 /

-0.89 (-4.97%)

AIMT Aimmune
$17.00 /

-0.89 (-4.97%)

Recommendations
Aimmune price target lowered to $15 from $30 at H.C. Wainwright » 07:20
05/12/20
05/12
07:20
05/12/20
07:20
AIMT

Aimmune

$17.89 /

+0.28 (+1.59%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein lowered the firm's price target on Aimmune to $15 from $30 and reiterates a Neutral rating on the shares following the company's Q1 results. Amid continued macro-environmental uncertainty, and the Palforzia launch moving to Q3 or Q4, the analyst reduced his year-end estimated 2020 revenue to $15M, down from $30M.

ShowHide Related Items >><<
AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
04/06/20 Citi
DBV's Viaskin Peanut more likely than not to be approved, says Citi
04/06/20 Piper Sandler
Aimmune launch 'thrown a wrench' amid COVID-19, says Piper Sandler
AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

Recommendations
Aimmune price target lowered to $20 from $32 at Stifel » 05:54
05/12/20
05/12
05:54
05/12/20
05:54
AIMT

Aimmune

$17.89 /

+0.28 (+1.59%)

Stifel analyst Derek…

Stifel analyst Derek Archila lowered the firm's price target on Aimmune Therapeutics to $20 from $32 and reiterates a Hold rating on the shares following last night's Q1 results. COVID-19 has had a material impact on Aimmune's ability to launch Palforzia and getting patients on therapy, leading the company to temporarily pause the launch, Archila tells investors in a research note. However, the analyst believes the impact of COVID-19 and expected easing of COVID-19 related closures in the second half of 2020 is already reflected in the current stock price. The shares will likely trade in a range until Aimmune can begin commercializing the product, probably towards the summer and fall months, assuming there is no second wave that could further stymie the launch, says Archila.

ShowHide Related Items >><<
AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
04/06/20 Citi
DBV's Viaskin Peanut more likely than not to be approved, says Citi
04/06/20 Piper Sandler
Aimmune launch 'thrown a wrench' amid COVID-19, says Piper Sandler
03/23/20 Cantor Fitzgerald
Aimmune price target lowered to $32 from $64 at Cantor Fitzgerald
AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

Recommendations
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler » 20:03
05/11/20
05/11
20:03
05/11/20
20:03
AIMT

Aimmune

$17.89 /

+0.28 (+1.59%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond keeps his Overweight rating and $60 price target on Aimmune after its Q1 update, saying the launch of its Palforzia drug has been slowed by COVID-19 outbreak. The analyst expects the uptake to remain slow in Q2 before picking up in the second half of the year as the economy reopens. In the mean time, Raymond sees Aimmune making progress on "securing formulary access and enrolling prescribers and patients in the Palforzia REMS program", adding that the revenue opportunity for the drug remains unchagned.

ShowHide Related Items >><<
AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

04/06/20 Citi
DBV's Viaskin Peanut more likely than not to be approved, says Citi
04/06/20 Piper Sandler
Aimmune launch 'thrown a wrench' amid COVID-19, says Piper Sandler
03/23/20 Cantor Fitzgerald
Aimmune price target lowered to $32 from $64 at Cantor Fitzgerald
03/18/20 JMP Securities
Aimmune downgraded to Market Perform from Outperform at JMP Securities
AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

On The Fly
Fly Intel: After-Hours Movers » 19:08
05/11/20
05/11
19:08
05/11/20
19:08
CBAY

CymaBay

$1.84 /

+0.045 (+2.51%)

, IIVI

II-VI

$36.29 /

+0.45 (+1.26%)

, VRRM

Verra Mobility

$9.12 /

+0.08 (+0.88%)

, SGRY

Surgery Partners

$10.82 /

-0.12 (-1.10%)

, GDOT

Green Dot

$30.78 /

-0.73 (-2.32%)

, GO

Grocery Outlet

$36.71 /

+0.01 (+0.03%)

, CZR

Caesars

$9.65 /

-0.06 (-0.62%)

, NVAX

Novavax

$24.59 /

+5.86 (+31.29%)

, AMC

AMC Entertainment

$5.32 /

+1.225 (+29.91%)

, EB

Eventbrite

$10.51 /

+0.26 (+2.54%)

, DIOD

Diodes

$50.09 /

-0.31 (-0.62%)

, ICAD

iCAD

$12.31 /

-0.55 (-4.28%)

, TLRY

Tilray

$8.09 /

+0.305 (+3.92%)

, TME

Tencent Music

$11.43 /

+0.39 (+3.53%)

, AIMT

Aimmune

$17.89 /

+0.28 (+1.59%)

, SGMO

Sangamo

$9.08 /

+0.4 (+4.61%)

, HALO

Halozyme

$24.82 /

+1.24 (+5.26%)

, FATE

Fate Therapeutics

$30.30 /

+1.45 (+5.03%)

, PLYA

Playa Hotels & Resorts

$2.11 /

+0.06 (+2.93%)

, JCOM

j2 Global

$81.40 /

+0.03 (+0.04%)

, SGMS

Scientific Games

$12.97 /

-0.18 (-1.37%)

, MAXR

Maxar Technologies

$11.61 /

+0.37 (+3.29%)

, FSCT

ForeScout

$32.12 /

-0.08 (-0.25%)

, OMER

Omeros

$17.01 /

+0.99 (+6.18%)

, SCPL

SciPlay

$12.22 /

+0.33 (+2.78%)

, HTZ

Hertz

$3.18 /

-0.07 (-2.15%)

, AKBA

Akebia

$12.85 /

+0.86 (+7.17%)

, QTWO

Q2 Holdings

$81.58 /

-1.04 (-1.26%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
CBAY CymaBay
$1.84 /

+0.045 (+2.51%)

03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
03/13/20 Oppenheimer
CymaBay upgraded to Outperform from Perform at Oppenheimer
03/13/20 Cantor Fitzgerald
CymaBay upgraded to Overweight from Neutral at Cantor Fitzgerald
02/26/20 Citi
Citi upgrades Intercept to Buy on peak sales potential of Ocaliva
IIVI II-VI
$36.29 /

+0.45 (+1.26%)

03/23/20
Fly Intel: Top analyst initiations
03/23/20 Barclays
Barclays starts II-VI with Overweight rating, $31 price target
03/23/20 Barclays
II-VI initiated with an Overweight at Barclays
03/20/20 Craig-Hallum
II-VI price target lowered to $35 from $45 at Craig-Hallum
VRRM Verra Mobility
$9.12 /

+0.08 (+0.88%)

04/29/20 Credit Suisse
Verra Mobility price target lowered to $10.50 from $17 at Credit Suisse
03/18/20 Deutsche Bank
Verra Mobility price target lowered to $12 from $18 at Deutsche Bank
01/24/20 Credit Suisse
Credit Suisse sees more M&A in 2020 for FinTechs, processors and payments
01/23/20 Credit Suisse
Verra Mobility initiated with an Outperform at Credit Suisse
SGRY Surgery Partners
$10.82 /

-0.12 (-1.10%)

04/27/20 Benchmark
Surgery Partners upgraded to Buy on faster recovery timeline at Benchmark
04/27/20 Benchmark
Surgery Partners upgraded to Buy from Hold at Benchmark
04/21/20
Envision bankruptcy report has limited read-throughs, says Benchmark
03/24/20 RBC Capital
Surgery Partners price target lowered to $14 from $19 at RBC Capital
GDOT Green Dot
$30.78 /

-0.73 (-2.32%)

04/07/20 Craig-Hallum
Green Dot assumed with a Buy at Craig-Hallum
03/26/20 SunTrust
Green Dot price target lowered to $40 from $48 at SunTrust
03/26/20 BTIG
BTIG upgrades Green Dot to Buy on 'game-changer' CEO hire
03/25/20 BTIG
Green Dot upgraded to Buy from Neutral at BTIG
GO Grocery Outlet
$36.71 /

+0.01 (+0.03%)

01/29/20
Fly Intel: Top five analyst initiations
01/29/20 Craig-Hallum
Grocery Outlet initiated with a Buy at Craig-Hallum
11/12/19 Jefferies
Grocery Outlet comps remain well above industry trend, says Jefferies
08/14/19 Jefferies
Grocery Outlet price target raised to $50 from $41 at Jefferies
CZR Caesars
$9.65 /

-0.06 (-0.62%)

04/17/20 SunTrust
Caesars, Twin River Worldwide upgraded to Buy from Hold at SunTrust
04/17/20 SunTrust
Caesars upgraded to Buy from Hold at SunTrust
04/06/20 Jefferies
Eldorado has 'considerable upside' from Caesars merger, says Jefferies
04/03/20 Stifel
Eldorado Resorts shares offer 250% upside from current levels, says Stifel
NVAX Novavax
$24.59 /

+5.86 (+31.29%)

04/30/20 H.C. Wainwright
Novavax price target raised to $33 from $24 at H.C. Wainwright
04/24/20 B. Riley FBR
Novavax price target raised to $29 from $20 at B. Riley FBR
04/09/20 Ladenburg
Ladenburg ups Novavax target to $28 on 'potent' COVID vaccine candidate
03/27/20 B. Riley FBR
Novavax price target raised to $20 from $15 at B. Riley FBR
AMC AMC Entertainment
$5.32 /

+1.225 (+29.91%)

05/11/20 B. Riley FBR
Amazon buyout may not appeal to AMC shareholders, says B. Riley FBR
04/30/20 Imperial Capital
AMC Entertainment price target raised to $3 from $2 at Imperial Capital
04/23/20 Macquarie
AMC Entertainment downgraded to Neutral from Outperform at Macquarie
04/22/20 JPMorgan
JPMorgan downgrades EPR after only15% of April rents get collected
EB Eventbrite
$10.51 /

+0.26 (+2.54%)

04/03/20 SunTrust
Eventbrite price target lowered to $8 from $19 at SunTrust
02/28/20 SunTrust
Eventbrite price target lowered to $19 from $22 at SunTrust
02/28/20 RBC Capital
Eventbrite downgraded to Sector Perform from Outperform at RBC Capital
01/24/20 William Blair
Data shows Eventbrite fan engagement is growing, says William Blair
DIOD Diodes
$50.09 /

-0.31 (-0.62%)

04/17/20 Baird
Diodes upgraded to Outperform at Baird
04/17/20 Baird
Diodes upgraded to Outperform from Neutral at Baird
03/19/20 Wells Fargo
Diodes price target lowered to $55 from $64 at Wells Fargo
02/10/20 Baird
Baird removes 'Fresh Pick Designation' on Diodes for China disruptions
ICAD iCAD
$12.31 /

-0.55 (-4.28%)

02/13/20 Craig-Hallum
iCAD price target raised to $15 from $9 at Craig-Hallum
02/05/20 JMP Securities
iCAD initiated with an Outperform at JMP Securities
01/09/20 Lake Street
Lake Street starts 'disruptive' iCAD with Buy rating, $14 price target
12/20/19
iCAD initiated with a Buy at Dougherty
TLRY Tilray
$8.09 /

+0.305 (+3.92%)

04/16/20 Jefferies
Tilray downgraded to Underperform following 'short squeeze' at Jefferies
04/16/20 Jefferies
Tilray downgraded to Underperform from Hold at Jefferies
04/09/20 Consumer Edge
Tilray downgraded to Equal Weight from Overweight at Consumer Edge
04/08/20 Raymond James
Ontario AG order positive for Canadian cannabis stocks, says Raymond James
TME Tencent Music
$11.43 /

+0.39 (+3.53%)

03/18/20 BOCOM
Tencent Music upgraded to Neutral from Sell at BOCOM
03/12/20 Morgan Stanley
Tencent Music upgraded to Overweight from Equal Weight at Morgan Stanley
02/25/20 Goldman Sachs
Huya downgraded to Neutral on cost inflation at Goldman Sachs
02/19/20
Fly Intel: Top five analyst downgrades
AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

04/06/20 Citi
DBV's Viaskin Peanut more likely than not to be approved, says Citi
04/06/20 Piper Sandler
Aimmune launch 'thrown a wrench' amid COVID-19, says Piper Sandler
03/23/20 Cantor Fitzgerald
Aimmune price target lowered to $32 from $64 at Cantor Fitzgerald
03/18/20 JMP Securities
Aimmune downgraded to Market Perform from Outperform at JMP Securities
SGMO Sangamo
$9.08 /

+0.4 (+4.61%)

02/28/20 William Blair
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
08/26/19
Fly Intel: Top five analyst initiations
08/26/19 H.C. Wainwright
Sangamo initiated with a Buy at H.C. Wainwright
HALO Halozyme
$24.82 /

+1.24 (+5.26%)

05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
02/05/20
Fly Intel: Top five analyst upgrades
02/05/20 Piper Sandler
Halozyme upgraded to Overweight from Neutral at Piper Sandler
FATE Fate Therapeutics
$30.30 /

+1.45 (+5.03%)

04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Citi
Fate Therapeutics price target raised to $41 from $26 at Citi
03/04/20 Barclays
Fate Therapeutics initiated with an Overweight at Barclays
PLYA Playa Hotels & Resorts
$2.11 /

+0.06 (+2.93%)

04/29/20 SunTrust
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/29/20 SunTrust
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/07/20 Citi
Playa Hotels & Resorts downgraded to Sell from Neutral at Citi
04/03/20 Deutsche Bank
Playa Hotels & Resorts price target lowered to $7 from $11 at Deutsche Bank
JCOM j2 Global
$81.40 /

+0.03 (+0.04%)

04/29/20
Fly Intel: Top five analyst initiations
04/29/20 JPMorgan
j2 Global initiated with an Overweight, $105 target at JPMorgan
04/29/20 JPMorgan
j2 Global initiated with an Overweight at JPMorgan
04/02/20
Fly Intel: Top five analyst initiations
SGMS Scientific Games
$12.97 /

-0.18 (-1.37%)

04/16/20 Jefferies
Gaming equipment suppliers 'managing around' fortunes of casinos, says Jefferies
04/15/20 Craig-Hallum
Scientific Games price target lowered to $20 from $55 at Craig-Hallum
02/20/20 Deutsche Bank
Scientific Games price target lowered to $23 from $29 at Deutsche Bank
02/19/20 Craig-Hallum
Scientific Games price target lowered to $55 from $60 at Craig-Hallum
MAXR Maxar Technologies
$11.61 /

+0.37 (+3.29%)

01/15/20 Credit Suisse
Maxar Technologies upgraded to Neutral from Underperform at Credit Suisse
01/08/20 JPMorgan
Maxar Technologies price target raised to $25 from $15 at JPMorgan
12/30/19 Raymond James
Maxar Technologies downgraded to Market Perform from Outperform at Raymond James
12/19/19 CIBC
Maxar Technologies upgraded to Neutral from Underperformer at CIBC
FSCT ForeScout
$32.12 /

-0.08 (-0.25%)

02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
02/07/20 Monness Crespi
ForeScout downgraded to Neutral from Buy at Monness Crespi
OMER Omeros
$17.01 /

+0.99 (+6.18%)

03/04/20 Wedbush
Omeros price target raised to $22 from $18 at Wedbush
03/03/20 Cantor Fitzgerald
Omeros shares can 'significantly rerate' from here, says Cantor Fitzgerald
11/05/19 H.C. Wainwright
Omeros recent selloff appears unwarranted, says H.C. Wainwright
SCPL SciPlay
$12.22 /

+0.33 (+2.78%)

04/22/20 BofA
SciPlay upgraded to Neutral from Underperform at BofA
04/22/20 BofA
SciPlay upgraded to Neutral from Underperform at BofA
04/17/20 SunTrust
SciPlay upgraded to Buy at SunTrust as a 'stay-at-home play'
04/17/20 SunTrust
SciPlay upgraded to Buy from Hold at SunTrust
HTZ Hertz
$3.18 /

-0.07 (-2.15%)

05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
AKBA Akebia
$12.85 /

+0.86 (+7.17%)

05/06/20 RBC Capital
Akebia price target raised to $12 from $8 at RBC Capital
05/05/20 Piper Sandler
Piper Sandler remains a buyer of Akebia following Phase 3 INNO2VATE data
05/05/20 Piper Sandler
Piper says efficacy, safety of FibroGen, Akebia drugs 'quite similar' in DD-CKD
05/05/20 Piper Sandler
Piper sees Akebia shares having 'nice follow through' on pre-market upside
QTWO Q2 Holdings
$81.58 /

-1.04 (-1.26%)

05/08/20 RBC Capital
Q2 Holdings price target raised to $92 from $73 at RBC Capital
04/29/20
Fly Intel: Top five analyst upgrades
04/29/20 Baird
Q2 Holdings upgraded to Outperform at Baird
04/29/20 Baird
Q2 Holdings upgraded to Outperform from Neutral at Baird
  • 13
    May
  • 12
    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.